Medtronic PLC $MDT Shares Purchased by CW Advisors LLC

CW Advisors LLC raised its holdings in Medtronic PLC (NYSE:MDT - Free Report) by 39.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 80,164 shares of the medical technology company's stock after acquiring an additional 22,855 shares during the quarter. CW Advisors LLC's holdings in Medtronic were worth $6,988,000 as of its most recent filing with the SEC.

• Medtronic Stock Finds Its Footing—Now It’s Gaining Momentum

Other institutional investors also recently made changes to their positions in the company. 1248 Management LLC acquired a new stake in shares of Medtronic in the first quarter valued at about $26,000. Twin Tree Management LP purchased a new position in Medtronic in the first quarter valued at about $29,000. Activest Wealth Management lifted its position in shares of Medtronic by 3,577.8% during the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company's stock valued at $30,000 after acquiring an additional 322 shares during the period. GFG Capital LLC purchased a new stake in shares of Medtronic during the 2nd quarter worth approximately $36,000. Finally, True Wealth Design LLC boosted its stake in shares of Medtronic by 49.8% during the 2nd quarter. True Wealth Design LLC now owns 421 shares of the medical technology company's stock worth $37,000 after acquiring an additional 140 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on MDT shares. Citigroup raised their price objective on Medtronic from $101.00 to $112.00 and gave the company a "buy" rating in a research note on Tuesday, October 7th. Morgan Stanley raised their price target on Medtronic from $107.00 to $117.00 and gave the company an "overweight" rating in a research report on Wednesday, November 19th. Robert W. Baird boosted their price objective on shares of Medtronic from $103.00 to $109.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 19th. Sanford C. Bernstein set a $111.00 price objective on shares of Medtronic in a research note on Wednesday, November 19th. Finally, Barclays lifted their target price on shares of Medtronic from $109.00 to $111.00 and gave the stock an "overweight" rating in a research report on Thursday, November 20th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $110.44.

• MarketBeat Week in Review – 08/18 - 08/22

Read Our Latest Research Report on Medtronic

Medtronic Trading Down 0.0%

Medtronic stock opened at $101.93 on Friday. The stock has a 50-day moving average price of $96.65 and a 200 day moving average price of $92.08. Medtronic PLC has a 52 week low of $79.29 and a 52 week high of $106.33. The stock has a market cap of $130.68 billion, a PE ratio of 27.47, a P/E/G ratio of 2.69 and a beta of 0.71. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57.

• Medtronic: The Opportunity Gets Healthier for Income Investors

Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.05. The company had revenue of $8.96 billion for the quarter, compared to analysts' expectations of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period last year, the company earned $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be paid a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic's payout ratio is presently 76.55%.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

Featured Stories

• Five stocks we like better than Medtronic
• Do ETFs Pay Dividends? What You Need to Know
• The Trade Desk: After a 70% Plunge, This Could Be The Time to Buy
• Russell 2000 Index, How Investors Use it For Profitable Trading
• Tap Into 2026 AI Infrastructure Gains With This High-Growth ETF
• What is the Dogs of the Dow Strategy? Overview and Examples
• Strong Quarter, Weak Reaction: Why GitLab Shares Dropped

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Medtronic Right Now?

Before you consider Medtronic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.

While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here